Description of four new genera and nine new species of Doryctinae (Hymenoptera: Braconidae) from French Guyana

From French Guyana four new genera of the subfamily Doryctinae Foerster, 1862 (Hymenoptera: Braconidae) with six new species (Lamquetia gen. nov.; type species: L. rufa Braet & van Achterberg, spec. nov., L. marshi Braet & Barbalho, spec. nov.), Ondigus gen. nov. (type species: O. bicolor spec. nov.), Neostaphius gen. nov. (type species: N. striatus spec. nov.), and Dapsilitas gen. nov. (type species: D. bicolor spec. nov.; D. robustisoma Braet & van Achterberg, spec. nov.) are described. In addition, three new species of the genera Achterbergia Marsh, 1993 (A. cornicoxa Braet & Barbalho, spec. no

Description of four new genera and nine new species of Doryctinae (Hymenoptera: Braconidae) from French Guyana

From French Guyana four new genera of the subfamily Doryctinae Foerster, 1862 (Hymenoptera: Braconidae) with six new species (Lamquetia gen. nov.; type species: L. rufa Braet & van Achterberg, spec. nov., L. marshi Braet & Barbalho, spec. nov.), Ondigus gen. nov. (type species: O. bicolor spec. nov.), Neostaphius gen. nov. (type species: N. striatus spec. nov.), and Dapsilitas gen. nov. (type species: D. bicolor spec. nov.; D. robustisoma Braet & van Achterberg, spec. nov.) are described. In addition, three new species of the genera Achterbergia Marsh, 1993 (A. cornicoxa Braet & Barbalho, spec. nov.), Aphelopsia Marsh, 1993 (A. striata Braet & Barbalho, spec. nov.) and Nervellius Roman, 1923 (N. exquisitus Braet & Barbalho, spec. nov.) are described. Additional distributional data on Achterbergia arawak Marsh, 1993; Aphelopsia annulicornis Marsh, 1993; and Ptesimogasteroides cerdai Braet & van Achterberg, 2001, are given. The internal microsculpture of the ovipositor of P. cerdai is illustrated. The genus Sharkeyelloides Marsh, 2002, is synonymized with Ptesimogastroides Braet & van Achterberg, 2001 (syn. nov.). Keys to the species of the genera Achterbergia Marsh, Aphelopsia Marsh, Nervellius Roman, Lamquetia gen. nov., Dapsilitas gen. nov. and Ptesimogastroides Braet & van Achterberg are given

At-admission prediction of mortality and pulmonary embolism in an international cohort of hospitalised patients with COVID-19 using statistical and machine learning methods

By September 2022, more than 600 million cases of SARS-CoV-2 infection have been reported globally, resulting in over 6.5 million deaths. COVID-19 mortality risk estimators are often, however, developed with small unrepresentative samples and with methodological limitations. It is highly important to develop predictive tools for pulmonary embolism (PE) in COVID-19 patients as one of the most severe preventable complications of COVID-19. Early recognition can help provide life-saving targeted anti-coagulation therapy right at admission. Using a dataset of more than 800,000 COVID-19 patients from an international cohort, we propose a cost-sensitive gradient-boosted machine learning model that predicts occurrence of PE and death at admission. Logistic regression, Cox proportional hazards models, and Shapley values were used to identify key predictors for PE and death. Our prediction model had a test AUROC of 75.9% and 74.2%, and sensitivities of 67.5% and 72.7% for PE and all-cause mortality respectively on a highly diverse and held-out test set. The PE prediction model was also evaluated on patients in UK and Spain separately with test results of 74.5% AUROC, 63.5% sensitivity and 78.9% AUROC, 95.7% sensitivity. Age, sex, region of admission, comorbidities (chronic cardiac and pulmonary disease, dementia, diabetes, hypertension, cancer, obesity, smoking), and symptoms (any, confusion, chest pain, fatigue, headache, fever, muscle or joint pain, shortness of breath) were the most important clinical predictors at admission. Age, overall presence of symptoms, shortness of breath, and hypertension were found to be key predictors for PE using our extreme gradient boosted model. This analysis based on the, until now, largest global dataset for this set of problems can inform hospital prioritisation policy and guide long term clinical research and decision-making for COVID-19 patients globally. Our machine learning model developed from an international cohort can serve to better regulate hospital risk prioritisation of at-risk patients. © The Author(s) 2024